Steven Stellman - Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: a pooled analysis

Version 1

      Publication Details (including relevant citation   information):

      Gammon, M. D., Sagiv, S. K., Eng, S. M., Shantakumar, S., Gaudet,   M. M., Teitelbaum, S. L., Britton, J. A., Terry, M. B., Wang, L.   W., Wang, Q., Stellman, S. D., Beyea, J., Hatch, M., Kabat, G.   C., Wolff, M. S., Levin, B., Neugut, A. I., Santella, R. M.   59 (12) 640-9-

      Abstract: Polycyclic aromatic hydrocarbon   (PAH)-DNA adducts have been associated with breast cancer in   several small studies. The authors' pooled analysis included 873   cases and 941 controls from a population-based case-control   study. Competitive enzyme-linked immunosorbent assay in   peripheral mononuclear cells was conducted in 2 rounds, and   results were pooled on the basis of round-specific quantiles. The   odds ratio for breast cancer was elevated in relation to   detectable PAH-DNA adducts (1.29 as compared with nondetectable   adduct levels; 95% confidence interval = 1.05, 1.58), but there   was no apparent dose-response relationship with increasing   quantiles. No consistent pattern emerged when the results were   stratified by PAH sources (e.g., active cigarette smoking or   PAH-containing foods), or when the cases were categorized by   stage of disease or hormone receptor status. These data provide   only modest support for an association between PAH-DNA adducts   and breast cancer development.

      Address (URL): http://www.ncbi.nlm.nih.gov/pubmed/16789472